Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus placebo effects on endogenous glucose production and glucagon in end-stage renal disease
2016-002268-15Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in end-stage kidney disease (ESKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Started Jun 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
end-stage kidney disease (ESKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002268-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002268-15.